Related Experiment Video
Updated: Jun 24, 2025
10:03
Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
Published on: November 11, 2016
9.8K
Biointerface-Engineered Hybrid Nanovesicles for Targeted Reprogramming of Tumor Microenvironment.
Xueyan Zhen1,2, Yongjiang Li2, Wanqing Yuan1,3
1School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, 710061, China.
Advanced Materials (Deerfield Beach, Fla.)
|June 9, 2024
Summary
Researchers developed a novel hybrid nanovesicle (P-I@M1E/AALs) to reprogram the tumor microenvironment (TME). This approach alleviates hypoxia and reprograms tumor-associated macrophages (TAMs) for enhanced antitumor therapy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cancer Therapy
Background:
- The tumor microenvironment (TME) in cancers like triple-negative breast cancer is characterized by hypoxia and immunosuppression, with tumor-associated macrophages (TAMs) being key players.
- M1-like macrophage-derived exosomes (M1-Exos) show promise for tumor targeting and macrophage polarization but suffer from low drug loading and stability.
- Existing therapies struggle to overcome the challenges posed by hypoxic and immunosuppressive TME.
Purpose of the Study:
- To develop a hybrid nanovesicle platform for enhanced antitumor therapy by addressing limitations of M1-Exos.
- To create a nanoplatform capable of alleviating tumor hypoxia and reprogramming TAMs.
- To investigate the synergistic therapeutic effects of combining photodynamic immunotherapy and TAM reprogramming.
Main Methods:
- Integration of M1-Exos with AS1411 aptamer-conjugated liposomes (AApt-Lips) to form M1E/AALs.
- Loading of M1E/AALs with perfluorotributylamine (PFTBA) and IR780 (P-I) to create P-I@M1E/AALs.
- Evaluation of P-I@M1E/AALs in a 4T1-tumor-bearing mouse model for TME reprogramming, immune cell infiltration, and antitumor efficacy.
Main Results:
- P-I@M1E/AALs successfully reprogrammed the TME by alleviating hypoxia and repolarizing TAMs towards an antitumor phenotype.
- The nanoplatform enhanced in situ reactive oxygen species generation and promoted T lymphocyte infiltration.
- Synergistic therapy using P-I@M1E/AALs significantly suppressed tumor growth and improved survival rates in mice.
Conclusions:
- The developed P-I@M1E/AAL nanoplatform offers a promising strategy for overcoming hypoxic and immunosuppressive TME.
- Targeted TAM reprogramming combined with enhanced photodynamic immunotherapy demonstrates significant therapeutic potential.
- This innovative hybrid nanovesicle platform represents a novel approach for treating challenging tumor types.
